The Food and Drug Administration's regulation of risk disclosure for implantable cardioverter defibrillators: has technology outpaced the Agency's regulatory framework?
作者信息
Basile Edward M, Lorell Beverly H
机构信息
King & Spaulding L.L.P., Washington, D.C., USA.
出版信息
Food Drug Law J. 2006;61(2):251-72.
PMID:16903031
Abstract
摘要
相似文献
1
2
Implants with flaws: disclosure and delay.
N Y Times Web. 2005 Jun 14:C1, C3.
3
Medical device preemption after Medtronic, Inc. v. Lohr.
Food Drug Law J. 1996;51(4):619-29.
4
Premarket approval and federal preemption of product liability claims in the wake of Medtronic, Inc. v. Lohr.
Food Drug Law J. 1996;51(4):613-8.
5
US and European postmarket clinical data requirements.
Med Device Technol. 2005 Mar;16(2):19-21.
6
Medical-device safety and the FDA.
N Engl J Med. 2008 Jul 3;359(1):88-9; author reply 89. doi: 10.1056/NEJMc086124.
7
The impact of FDA reform.
Med Device Technol. 2003 Apr;14(3):36-7.
8
Who should protect the public? The Supreme Court and medical device regulation.
N Engl J Med. 2007 Oct 25;357(17):1680-1. doi: 10.1056/NEJMp078142.
9
Semper fidelis--consumer protection for patients with implanted medical devices.
N Engl J Med. 2008 Mar 6;358(10):985-7. doi: 10.1056/NEJMp0800495.
10
Guidant's oops, three years later.
Mater Manag Health Care. 2005 Jul;14(7):8.
Zotero 插件